Clinical trial · Interventional
Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer
NCT01760694CI-TRIAL-00015393terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of enrollment
Summary
Brief summary (as posted)
To assess the ability of a combination of updated and approved modalities in the treatment of first line pancreatic cancer patients to increase the time to Progression Free Survival
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multi-Modality; IORT, Surgery, Radiation, Chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Resectable Patients
- description
- Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
- interventionNames
- Other: Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
- type
- EXPERIMENTAL
- label
- Marginally Resectable Patients
- description
- 2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
- interventionNames
- Other: Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven Exocrine Adenocarcinoma of the pancreas * Clinically resectable or marginally resectable disease * No prior radiation or chemotherapy for carcinoma of the pancreas * ECOG performance status of 0-1 * Patients must be medically able to undergo surgical resection * Patients of child bearing potential must follow study specific precautions * Women that are lactating will not be excluded on the condition that they dispose their breast milk. * Adequate hematologic and biochemical parameters. Exclusion Criteria: * Prior treatment for pancreatic cancer. * Concurrent investigational treatments. * Unresectable pancreatic mass. * Neuroendocrine Histological pancreatic cancer * Distant Metastatic disease * Any condition that, in the option of the investigator, would compromise the well being of the patient or anything that would prevent the patient from meeting or performing study requirements
References
Publications (0)
Data not yet available
No reference posted for this study.